<DOC>
	<DOCNO>NCT01456078</DOCNO>
	<brief_summary>By improved kidney dosimetry include biological effective dose take account potential risk factor ( especially kidney toxicity ) , might possible give optimal personalize treatment 177Lu-DOTA-TATE patient metastatic neuroendocrine tumor .</brief_summary>
	<brief_title>A Multicenter Study Evaluating Efficacy Safety 177Lu-DOTA-TATE Based Kidney-Dosimetry Patients With Disseminated Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Step 1 : ECOG 02 Histologically verify neuroendocrine tumor Ki67 least 20 % least 20 mitoses/high power field . If tissue determination base several year old , investigator consider option acquire new determination , especially behaviour tumor change since diagnosis Metastatic disease complete resection consider possible feasible Measurable disease Radiological disease progression last 14 month The large metastasis uptake 111Inoctreotide great uptake liver planar scintigraphy . Metastases small , locate centrally , evaluate SPECT enable correct estimation relative uptake . The majority tumor burden must demonstrate increased uptake lutetiumtreatment consider Stable dose somatostatin analogue past 3 month Estimated survival 6 month ANC 1.5 x 10 9/L Bilirubin less 1.5 x upper limit normal GFR 50 ml/min . Signed write informed concent Step 2 : Continues fulfill inclusion criterion , none exclusion criterion , step 1 A maintain GFR ( less 40 % decrease compare baseline AND GFR 50 ml/min ) The treatment step 1 administer maximal interval 12 week Age 70 year Step 1 : Performance Status ECOG 34 Proliferation index ( Ki67 ) 20 % 20 mitoses/hpf Locoregional treatment last 3 month involve measurable lesion Chemotherapy last 3 month , long persist toxicity exists . Earlier treatment mTORi TKI permit Other concommitant nephrotoxic treatment Modifications somatostatine dose last 3 month Serious heart disease Previous radiotherapy include 25 % active bone marrow volume Pregnancy lactation Extensive liver metastasis ( 50 % liver volume ) Symptomatic CNS metastases require corticosteroid treatment Ongoing treatment interferon . This treatment suspend minimum 4 week treatment 177LuDOTATATE , long persist sign toxicity Patients another metastatic tumor diagnosis Step 2 : Progressive disease since start study treatment Organ toxicity grade 34 step 1 Serious hematological toxicity previous treatment cycle ( ANC less 0.5 x 10 9 platelet less 50.0 x 10 9 ) Longstanding diabetes ( 8 year ) . Patients wellcontrolled diabetes history le 8 year blood pressure le 130/80 albuminuria ( albumin/creatinine index ) include Hypertension , i.e . 160/90 ( diabetic 130/80 ) . Antihypertensive pharmacological treatment permit long manifest albuminuria Previous liver embolisation Previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>177Lu-DOTA-TATE</keyword>
	<keyword>Safety</keyword>
	<keyword>Kidney dosimetry</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Neuroendocrine tumor , liver metastasis .</keyword>
</DOC>